Drug Profile
Gebasaxturev - Viralytics
Alternative Names: CAV21; Cavatak; Coxsackievirus A21; CVA 21; V 937Latest Information Update: 05 Apr 2024
Price :
$50 *
At a glance
- Originator ViroTarg
- Developer Merck & Co; Viralytics
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action CD55 antigen inhibitors; Cell death stimulants; Intercellular adhesion molecule-1 antagonists
-
Orphan Drug Status
Yes - Malignant melanoma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
- No development reported Bladder cancer; Chronic lymphocytic leukaemia; Glioma; Lung cancer; Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Uveal melanoma
Most Recent Events
- 20 Mar 2024 Merck & Co terminates a phase I/II trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Canada, France, Japan, Israel, Italy, Germany, Hungary, Norway, Peru, Poland, Portugal, Spain, USA, Taiwan (Intratumoural), due to business reasons (EudraCT2020-001908-42) (NCT04521621)
- 01 Mar 2024 Merck & Co terminated a phase II trial in Malignant melanoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Australia, Chile, France, Germany, Israel, Italy, Norway, Spain, South Korea, South Africa, New Zealand, the UK, and the US (Intratumoural) (IV) due to business reasons (NCT04152863)
- 25 Jul 2023 Merck & Co completes a phase I/II trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Canada, France, Japan, Israel, Italy, Germany, Hungary, Norway, Peru, Poland, Portugal, Spain, USA, Taiwan (Intratumoural) (EudraCT2020-001908-42) (NCT04521621)